Replies to post #37376 on CYduct Diagnostics Inc (CYDX)

[mgrego]

I really appreciate the information and the time you took. Your DD is top notch. The doctor you spoke to really provided some really great information and seemed to have nothing but good things to say about the company.

I was familiar with the PR regarding the use of SNDY products at the NIH but obviously did not want to make any assumptions as to what capacity and to what extent their products were being utilized in their research. I admit, I took the PR at face value and did not think Solos products were currently playing that large of a role. Breast cancer research has and will continue to be focused on more efficient diagnosis and treatment in addition to the underlying genetic disposition of the disease. Solos would seem to be playing a future role.

The fact that Solos technology has been used at the NIH for 6-8 years is very telling information. I must say I am shocked to here this. In techological adoption, government research institutions are often one of the first to adopt cutting edge technology. I have mentioned before technological adoption in the medical device industry is often slow. You often see a "lag period" between the time of early adoptors and more widespread adoption (which is often exponential). The company touting future growth may be coinciding with the end of this lag period. We should begin to see an increased focus in sales and marketing by the company.

It is now very likely that SNDY products do have a competitive advantage in the marketplace in the form of top notch video imaging. The price factor compared to competitors products will allow them to rapidly gain market share both domestically and abroad. Think CE Mark certification, EU market, and a substantial cost advantage using Solos products (30K vs. 100K). They could increase prices 100% and still be more cost effective .

I couldn't agree more about your comment about PPS. It may be hard to accept but PPS is not important at this time. You are entering at the ground floor of a company with an extremely bright future.

Again Great DD. I look forward to any follow up information you are able to provide.

GLTA

[lchase01]

The profile for this doctor is here:

http://ccr.cancer.gov/staff/staff.asp?profileid=5760

This is real stuff! I lost some money on another penny stock this week that is looking more and more, if not already identified as, a scam of the biggest order. This stock is solid.

[ajsollii]

And this is exactly why the CE Mark will be huge. Europe has a fairly socialized medical system. So cheaper but better is exactly what they'll be looking for. With increased marketing in the US, hopefully it takes over for the big boys and their old toys. I'm long. And expect to make a lot of money. Not hope...expect. Good luck all.

[highflier]

Tradetalker great DD on your part. This is the kind of information we have to have to know what is really going on behind the scenes. I have a close friend that found some really nice information out for us about SNDY products. She is a rep for the medical instrument field and knows some doctors that are heavy into the endoscopy field. Several doctors she talked to gave SNDY very high marks on their equipment. This was one of the first things I did before we really got deep into this stock. It is great to have another expert backing up what we had found out. Kudos to you. This is how you know what you own. Great job again.

There is some other information I am working on finalizing on SNDY. I told you guys last week I hope to have some really big information soon.

Take care my friend,
Mike

[Braden32601]

WOW Great News and DD!!!

[pennybaby]

Awesome stuff! I think this should be stickied.

[Tradetalker]

Folks, I haven't posted much lately but wanted to reiterate confidence in this company. They have been a gamechanger in the research community and increasingly in the private sector. Google Dr. Jill Dietz at the Cleveland Clinic, and check out this conversation I had with a NIH surgeon. SNDY like no other has been a gamechanger for NIH doctors involved in breast cancer research. No speculation there whatsoever. GLTA.